XBIT · Company research
XBiotech Inc (XBIT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire | XBiotech announced positive Phase II results for its anti-IL-1α monoclonal antibody vilamakitug (Natrunix) in treating refractory metastatic colorectal cancer. The investigator-sponsored TASKIN trial met its primary efficacy endpoint with 61.3% 12-month overall survival in the treatment arm versus 55.7% in the control arm. Notably, exploratory analysis showed a statistically significant 62% reduction in death risk for right-sided colon tumors, a historically aggressive subtype with high unmet medical needs. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| XBiotech gibt positive endgültige Wirksamkeitsergebnisse der Phase-II-Studie „TASKIN“ bekannt, einer von Forschern initiierten Studie zur Behandlung von refraktärem metastasiertem Kolorektalkarzinom | XBiotech announced positive final efficacy results from the Phase II TASKIN trial of its anti-IL-1α monoclonal antibody Vilamakitug (XB2001) combined with standard chemotherapy for refractory metastatic colorectal cancer. The study met its primary efficacy endpoint with a 12-month overall survival rate of 61.3% versus 55.7% in the control group. An exploratory subgroup analysis showed a statistically significant 62% reduction in mortality risk for patients with right-sided tumors. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer | XBiotech announced positive Phase II results from the TASKIN trial showing its anti-IL-1α monoclonal antibody vilamakitug (XB2001) met primary efficacy criteria with 61.3% 12-month overall survival in refractory metastatic colorectal cancer patients. An exploratory analysis revealed significant survival benefits in right-sided tumors, with a 62% reduction in death risk compared to control. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| An exploratory analysis found 62% lower death risk versus control for right-sided colon tumors - Stock Titan | An exploratory analysis found 62% lower death risk versus control for right-sided colon tumors Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| XBIT Forecast — Price Target — Prediction for 2027 - TradingView | XBIT Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Oct 8, 2026 | neutral | 0 | 0.6 |
| XBiotech Inc. SEC Filing (Oct 2, 2026) - Stock Titan | XBiotech Inc. SEC Filing (Oct 2, 2026) Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| XBiotech (XBIT) Stock Analysis Report | Financials & Insights - Benzinga France | XBiotech (XBIT) Stock Analysis Report | Financials & Insights Benzinga France | View source ↗ | Benzinga France | Sep 27, 2026 | neutral | 0 | 0.6 |
| XBiotech (XBIT) Move: Advances 0.22% to $2.30 for the Current Session; Current Setup: Price Remains Between $2.18 Support and $2.42 Resistance at the Close - Initial Balance - dars.gov.et | XBiotech (XBIT) Move: Advances 0.22% to $2.30 for the Current Session; Current Setup: Price Remains Between $2.18 Support and $2.42 Resistance at the Close - Initial Balance dars.gov.et | View source ↗ | dars.gov.et | Aug 24, 2026 | neutral | 0 | 0.6 |
| XBiotech (XBIT) Move: Advances 0.22% to $2.30 for the Current Session; Current Setup: Price Remains Between $2.18 Support and $2.42 Resistance at the Close - Bull Flag - dars.gov.et | XBiotech (XBIT) Move: Advances 0.22% to $2.30 for the Current Session; Current Setup: Price Remains Between $2.18 Support and $2.42 Resistance at the Close - Bull Flag dars.gov.et | View source ↗ | dars.gov.et | Aug 24, 2026 | neutral | 0 | 0.6 |
| XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - GlobeNewswire | XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis GlobeNewswire | View source ↗ | GlobeNewswire | Jun 15, 2026 | neutral | 0 | 0.6 |
| XBIT stock slips as Xbiotech shows $69.2M market cap - AD HOC NEWS | XBIT stock slips as Xbiotech shows $69.2M market cap AD HOC NEWS | View source ↗ | AD HOC NEWS | Feb 9, 2026 | neutral | 0 | 0.6 |
| XBiotech: Several Shots On Goal In Big Target Market Indications (NASDAQ:XBIT) - Seeking Alpha | XBiotech: Several Shots On Goal In Big Target Market Indications (NASDAQ:XBIT) Seeking Alpha | View source ↗ | Seeking Alpha | May 24, 2024 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Jan 10, 2024 | neutral | 0 | 0.6 |
| Xbiotech Stock Price Forecast. Should You Buy XBIT? - StockInvest.us | Xbiotech Stock Price Forecast. Should You Buy XBIT? StockInvest.us | View source ↗ | StockInvest.us | Dec 2, 2020 | neutral | 0 | 0.6 |
| XBiotech Inc. (XBIT) Stock Price, News, Quote & History - Yahoo! Finance Canada | XBiotech Inc. (XBIT) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | May 20, 2017 | neutral | 0 | 0.6 |
| XBiotech Inc. (XBIT) stock price, news, quote and history - Yahoo Finance UK | XBiotech Inc. (XBIT) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | May 18, 2017 | neutral | 0 | 0.6 |
| XBiotech (XBIT) Stock Price, News & Analysis $XBIT - MarketBeat | XBiotech (XBIT) Stock Price, News & Analysis $XBIT MarketBeat | View source ↗ | MarketBeat | Aug 14, 2016 | neutral | 0 | 0.6 |
| XBIT: XBiotech Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | XBIT: XBiotech Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Nov 24, 2015 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.